In order to determine the effects of daratumumab and hcAbs on the enzyme activities of CD38-expressing tumor cells, we applied the HPLC assay described in Figure 1, to analyze the conversion of NAD+ to ADPR and cADPR, in the absence or presence of antibodies. This evidence concerns the gene CD38 and neoplasm.